We recently published 10 Easy Double-Digit Gainers. Roivant Sciences Ltd. (NASDAQ:ROIV) was one of the best performers last week.
Roivant saw its share prices jump by 19.4 percent week-on-week, hitting a new all-time high, as investors snapped up shares following encouraging results from its pipeline projects, with one already seeking a new drug application (NDA) approval.
In Friday’s trading, the stock jumped to its highest price of $25.95 before trimming a few cents to finish the day just up by 22.14 percent at $25.82 apiece.
Photo grabbed from Roivant Sciences website
In an updated report, Roivant Sciences Ltd. (NASDAQ:ROIV) said that its unit, Priovant, saw strong results from its clinical trial of Brepocitinib in patients with cutaneous sarcoidosis (CS), having achieved a 22.3 percent improvement in CSAMI-A score—a measure of cutaneous sarcoidosis disease activity—after a 16-week therapy. This compares with a 0.7 percent improvement in the placebo group.
Meanwhile, Priovant has submitted an NDA with the Food and Drug Administration for the approval of brepocitinib to treat dermatomyositis.
A third clinical trial to check the efficacy of the therapy candidate for patients with non-infectious uveitis (NIU) is expected in the second half of calendar year 2026.
Meanwhile, Roivant Sciences Ltd. (NASDAQ:ROIV), through its other business units Immunovant and Pulmovant are underway with the clinical trials of other therapy candidates for the treatment of difficult-to-treat rheumatoid arthritis, Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropath, Sjögren’s disease, and cutaneous lupus erythematosus, as well as pulmonary hypertension.
On Friday, Roivant Sciences Ltd. (NASDAQ:ROIV) also reported dismal earnings performance for the third quarter ending December 31, with the company swinging to a net loss attributable to shareholders of $265.89 million versus a $169 million attributable net income in the same period a year earlier.
The figure brought its attributable net loss in the nine-month period to $602.76 million, versus a $34.49 million attributable net income in the same period a year earlier.
While we acknowledge the potential of ROIV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
